Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)

Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with acute aortic syndrome (AAS). Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with thymosin alpha 1 in addition to antiinflammatory treatment may be beneficial. This study was designed to test the hypothesis that the administration of Ulinastatin and Thymosin α1 during the acute phase of AAS will result in a reduced incidence of SIRS and MODS.

NCT Number	NCT06966687
Lead Sponsor	Nanjing Medical University Collaborators: Beijing Anzhen Hospital, West China Hospital, Shanghai East Hospital of Tongji University, The First Affiliated Hospital of Guangzhou Medical University
Conditions	Aortic Dissection, Aortic Dissection Aneurysm
Enrollment	200 participants
Start Date	2025-04-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-14